Absorb GT1 Bioresorbable Vascular Scaffold System is withdrawn from all markets.- Abbott.
Abbott has withdrawn its first-generation fully absorbable vascular scaffold , Absorb GT1 Bioresorbable Vascular Scaffold System (BVS) from the global market due to low commercial sales. All sizes of its BVS and its Absorb GT1 Bioresorbable Vascular Scaffold System (BVS) were discontinued as of 14 September 2017.
Absorb was , approved by the FDA in July 2016, was designed to limit scar tissue growth and fully resorb over the course of about three years in implanted patients with coronary artery disease.
The company plans to keep working on a next generation bioresorbable device, arguing that the technology �offers patients the possibility of live without permanent metallic implants.� It will also continue to monitor long-term outcomes in existing trials.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
4 mins